Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and MedImmune, the global biologics research and development arm of AstraZeneca, today announced …
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced two research projects involving the company’sLm Technology™ immunotherapy candidate ADXS-PSA, which is …
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has granted U.
Advaxis, Inc.(NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has appointed Shelonitda S.
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that its president and chief executive officer, Daniel O’Connor was selected as …
H.C.
This morning, Advaxis Inc. (NASDAQ:ADXS) held a conference call to provided an update on its pipeline programs and laid out a timeline for multiple milestones …
MLV analyst Raghuram Selvaraju was out pounding the table on Advaxis, Inc. (NASDAQ:ADXS) Friday, reiterating a Buy rating on the stock with a price target of …
Aduro BioTech Inc’s (NASDAQ:ADRO) long awaited public debut has arrived. As expected, the hype for immunotherapies spilled over to Aduro as the company …
